Abeona Therapeutics (NASDAQ:ABEO) Director Sells $91,950.85 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Leila Alland sold 18,065 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total value of $91,950.85. Following the transaction, the director owned 173,614 shares of the company’s stock, valued at $883,695.26. This represents a 9.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Abeona Therapeutics Stock Down 3.6%

Shares of ABEO opened at $5.08 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The stock has a market capitalization of $275.29 million, a price-to-earnings ratio of 4.13 and a beta of 1.18. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The business’s 50 day simple moving average is $5.17 and its 200-day simple moving average is $5.58.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, equities analysts expect that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research note on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Institutional Trading of Abeona Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Boone Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the second quarter worth $7,126,000. AWM Investment Company Inc. bought a new position in shares of Abeona Therapeutics in the second quarter worth about $2,670,000. Y Intercept Hong Kong Ltd purchased a new position in Abeona Therapeutics in the 2nd quarter worth about $581,000. Simplify Asset Management Inc. lifted its holdings in Abeona Therapeutics by 36.7% during the 2nd quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock valued at $3,173,000 after buying an additional 150,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Abeona Therapeutics in the 2nd quarter valued at about $1,523,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.